The prognostic significance of IGHV SHM status, along with the restrictions in the immunoglobulin rearrangements’ gene repertoire and B-cell receptor stereotypy, have provided key evidence that BCR (auto)antigenic stimulation drives the leukemogenesis and progression of CLL [66,67]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.